Pulmonx (STU:4NI) Common Stock : €0.04 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Pulmonx Common Stock?

Pulmonx's quarterly common stock stayed the same from Sep. 2023 (€0.04 Mil) to Dec. 2023 (€0.04 Mil) and stayed the same from Dec. 2023 (€0.04 Mil) to Mar. 2024 (€0.04 Mil).

Pulmonx's annual common stock increased from Dec. 2021 (€0.03 Mil) to Dec. 2022 (€0.04 Mil) but then stayed the same from Dec. 2022 (€0.04 Mil) to Dec. 2023 (€0.04 Mil).

Pulmonx Common Stock Historical Data

The historical data trend for Pulmonx's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulmonx Common Stock Chart

Pulmonx Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.03

0.04

Pulmonx Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															0.04	0.04	0.04	0.04	0.04

Pulmonx Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Pulmonx (STU:4NI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulmonx Corp (STU:4NI) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

LUNG:USA

Address

700 Chesapeake Drive, Redwood, CA, USA, 94063

Website

https://www.pulmonx.com

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.

Pulmonx (STU:4NI) Headlines

No Headlines